[The influence of simvastatin on hsCRP and some paramneters of hemostasis in patients with ischemic heart disease].
Inflammation and disturbances of the hemostatic system may play a role in pathogenesis and complications of ischemic heart disease. More and more reports indicate that apart from their cholesterol-lowering effect statins also exert other beneficial effects in cardiovascular diseases. Taking this into consideration, the aim of the study was to assess the influence of simvastatin (20 mg per day) on a marker of inflammation - CRP and some parameters of coagulation and fibrinolysis in 22 patients with ischaemic heart disease. Serum lipids, levels of hsCRP, thrombomodulin (TM), vWF, prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), thrombin activatable fibrinolysis inhibitor (TAFI), t-PA, plasmin-antiplasmin complex (PAP) and TAFI activity were assessed before and after one, three and six months simvastatin treatment. After one month therapy of simvastatin, there have been significant reduction of levels of total cholesterol, LDL-cholesterol and triglycerides and these values have remained until the end of the study. No influence on the level of HDL-cholesterol has been observed. After 6 months of treatment significant decrease in the level of hsCRP and increase of the levels TM and vWF with reference to baselines results have been observed. After a 1-and 6-month therapy, the level of TAFI have been significantly increased. Other hemostatic parameters, i.e. levels of F1+2, TAT, t-PA, PAP and TAFI activity have not changed significantly. This prospective study has confirmed high efficacy of lipid-lowering effect and anti-inflammatory properties of simvastatin. Simvastatin influenced some hemo-static parameters, however, these effects were not, in majority, significant.
Stogowska-Nikiciuk
Barbara
B
Oddział Kardiologii SP ZOZ Wojewódzkiego Szpitala Zespolonego im. J. Sniadeckiego w Białymstoku. basia_stogowska@poczta.onet.pl
Małyszko
Jolanta
J
Małyszko
Jacek Stanisław
JS
Pawlak
Krystyna
K
Myśliwiec
Michał
M
D000368:Aged; D002097:C-Reactive Protein / Q000187:drug effects*; D025901:Carboxypeptidase B2 / Q000378:metabolism / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control*; D009205:Myocarditis / Q000150:complications / Q000378:metabolism / Q000517:prevention & control; D019821:Simvastatin / Q000494:pharmacology*; D018180:Thrombomodulin / Q000187:drug effects; D014280:Triglycerides / Q000097:blood
D008078:Cholesterol, LDL; D018180:Thrombomodulin; D014280:Triglycerides; D002097:C-Reactive Protein; D002784:Cholesterol; D019821:Simvastatin; D025901:Carboxypeptidase B2